News

The Google offering will assist providers like Cleveland Clinic to create a new kind of healthcare experience that puts the patient in charge of his or her own

Fenoglide will be the lowest dose of fenofibrate available for patients. Fenoglide will be offered in 40mg and 120mg strength tablets. Fenoglide utilizes LCP’s unique MeltDose technology, a

Under terms of the agreement, Quest Diagnostics will generally have the exclusive right to provide full-service medical screening and diagnostic testing of life insurance candidates, and related administrative

The study investigated the response of the T-SPOT.TB assay in 33 subjects with culture confirmed TB. T-SPOT.TB was positive in 83% of the subjects who had received less

The drops have already been launched in Spain, Portugal, the Czech Republic and Canada and it is expected that they will be launched in Jordan and Mexico during

The continuation of the trial following this interim analysis triggers a milestone payment to Oxford BioMedica of E10 million. TroVax is Oxford BioMedica’s novel cancer immunotherapy product, which

RBT has developed a proprietary method for skin whitening through the use of an enzyme derived from a harmless fungus. The RBT product can also be used to

As of February 20, 2008, shares of Visicu common stock will no longer be listed on the NASDAQ.

XELR8 will issue 500,000 unregistered common shares at $1 per share and 300,000 new warrants exercisable at $1.50 per share. In addition, as part of the new funding,